MAIC: ALPINE vs. ASCEND

Disease State: Chronic lymphocytic leukemia

MAIC between ALPINE & ASCEND: A matching-adjusted indirect comparison (MAIC) was conducted using individual patient data from the ALPINE trial and aggregate data from the ASCEND trial to compare the efficacy of zanubrutinib and acalabrutinib in patients with relapsed/refractory CLL.

Reading
8 Aug 2025

CaDAnCe-101 (NCT05006716) is a Phase 1/2, open-label, dose-escalation and expansion trial evaluating BGB-16673, a Bruton tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma (FL), and marginal zone lymphoma (MZL).

Reading
8 Aug 2025

CELESTIAL-TN CLL (NCT06073821) is a global, Phase 3, open-label, randomized trial comparing sonrotoclax plus zanubrutinib with venetoclax plus obinutuzumab in patients with previously untreated chronic lymphocytic leukemia (CLL).

Reading
8 Aug 2025

MAIC: ALPINE vs. ASCEND

MAIC between ALPINE & ASCEND: A matching-adjusted indirect comparison (MAIC) was conducted using individual patient data from the ALPINE trial and aggregate data from the ASCEND trial to compare the efficacy of zanubrutinib and acalabrutinib in patients with relapsed/refractory CLL.

Reading
8 Aug 2025

CaDAnCe-101 Trial

CaDAnCe-101 (NCT05006716) is a Phase 1/2, open-label, dose-escalation and expansion trial evaluating BGB-16673, a Bruton tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma (FL), and marginal zone lymphoma (MZL).

Reading
8 Aug 2025